Abstract:Abstract Introduction: PD-1 blockade has achieved great success in the clinic. However, only a small subset of patients benefits from the treatment and most responders develop acquired resistance thereafter. One of the resistance mechanisms is beta-2-microglobulin (β2M) mutation mediated dysfunction of MHC-I antigen presentation, which contributes to attenuation of cellular cytotoxicity triggered by adaptive CD8+ T cells. Activating innate immunity, such as natural killer (NK) cells, can be used as a strategy to circumvent the attenuation. Immune-stimulating agents like Stimulator of interferon genes (STING) agonists and Toll-like receptor (TLR) 7/8 agonists can elicit NK cell-mediated tumor rejection in preclinical tumor models, independent of CD8+ T cells. Thus, to evaluate novel therapeutic strategies overcoming anti-PD-1 resistance, we established a MC38-OVA-β2M KO tumor model. Methods: We knocked out β2M genes in a murine MC38-OVA colorectal cancer cell line using CRISPR/Cas9 to generate MC38-OVA-β2M KO cells. β2M knockout was verified by western blot and flow cytometry. For in vitro testing, both MC38-OVA and MC38-OVA-β2M KO cells were treated with IFN-α, IFN-β and IFN-γ for 24h, and then MHC-I and OVA peptide SIINFEKL expression were analyzed by flow cytometry. For in vivo testing, 1 × 106 MC38-OVA cells and MC38-OVA-β2M KO cells were subcutaneously injected into C57BL/6 mice and the models were treated with anti-PD-1. Finally, the MC38-OVA-β2M KO tumor model was treated with anti-PD-1, cyclic nucleotides (CDN), R-848 and anti-PD-1 combined with either CDN or R-848. At the endpoint, the composition of immune cells in spleens were analyzed by flow cytometry. Results: Following confirmation of β2M knockout, MHC-I expression and MHC-I-OVA peptide presentation were also diminished on MC38-OVA-β2M KO cells, even after treatment of IFN- α, IFN-β, or IFN-γ. In vivo, anti-tumor efficacy of PD-1 blockade was significantly diminished in MC38-OVA-β2M KO model (TGI=31%, p<0.001), compared to MC38-OVA model (TGI=91%). To overcome the resistance, CDN, a STING agonist or R-848, a TLR7/8 agonist was administered alone or combined with anti-PD-1 in the MC38-OVA-β2M KO model. Single treatment of either CDN (TGI=73%) or R-848 (TGI=89%) markedly impeded tumor growth, and combination with anti-PD1 greatly enhanced their anti-tumor effects (TGI of 98% and 99%, respectively). Additionally, flow cytometry analysis showed a decrease of Myeloid-derived suppressor cells (MDSCs) and an increase of NK cells in spleens of the mice treated with CDN and anti-PD-1. In parallel, a decrease of MDSCs was also observed in the mice with combined treatment of R-848 and anti-PD-1. Conclusion: The successfully established MC38-OVA-β2M KO model is a useful tool for investigating therapeutic strategies to overcome MHC-I down-regulation mediated immunotherapy resistance. Moreover, STING agonists and TLR7/8 agonists may be potential candidates. Citation Format: Li Hua, Chenpan Nie, Jie Lin, Annie Xiaoyu An, Ludovic Bourre, Jingjing Wang. STING agonist and TLR7/8 agonist overcome anti-PD-1 resistance mediated by loss of β2M. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5118.

STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation

Impact of in vivo fate of STING agonist-loaded lipid nanoparticles on antitumor immunity

Cancer Immunotherapy with Lipid Nanoparticles Loaded with a Stimulator of Interferon Genes Agonist against Renal Tumor Lung Metastasis

Dual Targeting of STING and PI3Kγ Eliminates Regulatory B Cells to Overcome STING Resistance for Pancreatic Cancer Immunotherapy

Abstract LB-126: Nanoparticle-incorporated STING Activator As an Immunotherapeutic for PD-L1 Resistant Triple-Negative Breast Cancer

Vaccination with a combination of STING agonist-loaded lipid nanoparticles and CpG-ODNs protects against lung metastasis via the induction of CD11bhighCD27low memory-like NK cells

An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases

STING Agonist Enhances the Efficacy of PD-L1 Monoclonal Antibody in Breast Cancer Immunotherapy by Activating the IFNβ Signaling Pathway

Combination of STING Agonist and CXCR3 Antagonist Disrupts Immune Tolerance to Overcome Anti-Pd-l1 Resistance in Lung Adenocarcinoma under Oxidative Stress.

STING Agonist‐Loaded Nanoparticles Promotes Positive Regulation of Type I Interferon‐Dependent Radioimmunotherapy in Rectal Cancer

Abstract 5118: STING Agonist and TLR7/8 Agonist Overcome Anti-Pd-1 Resistance Mediated by Loss of Β2m

Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses

Nanodrug shows spatiotemporally controlled release of anti-PD-L1 antibody and STING agonist to effectively inhibit tumor progression after radiofrequency ablation

Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration

Potentiating the Systemic Immunity by Bacteria‐Delivered Sting Activation in a Tumor Microenvironment

Overcoming Pancreatic Cancer Immune Resistance by Codelivery of CCR2 Antagonist Using a STING-activating Gemcitabine-Based Nanocarrier.

Tumor Microenvironment‐Responsive Nanoparticles Amplifying STING Signaling Pathway for Cancer Immunotherapy

A Nanoparticle-Incorporated STING Activator Enhances Antitumor Immunity in PD-L1-insensitive Models of Triple-Negative Breast Cancer.

Abstract 6534: Overcoming B regulatory cell induced STING resistance by dual functional albumin nanomedicine to prolong survival of pancreatic cancer

STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity

Antagonism of regulatory ISGs enhances the anti-melanoma efficacy of STING agonists